These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Author: Ou D, Levy A, Blanchard P, Nguyen F, Garberis I, Casiraghi O, Scoazec JY, Janot F, Temam S, Deutsch E, Tao Y.
    Journal: Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182.
    Abstract:
    OBJECTIVES: The optimal concurrent regimen, chemoradiotherapy (CRT) or bioradiotherapy (BRT), in locally advanced head and neck squamous cell carcinoma (LAHNSCC) remains controversial, especially in human papilloma virus-associated patients. MATERIAL AND METHODS: Data of 265 patients with LAHNSCC treated with CRT (cisplatin, 100mg/m(2) every 3weeks, n=194) or BRT (weekly cetuximab, n=71), including 119 patients with known HPV/p16 status were analyzed. RESULTS: Median follow-up was 54.5months. The 5-year progression-free survival (PFS) and locoregional control (LRC) were 51.7% vs. 36.9% (p=0.01) and 74.2% vs. 51.2% (p=0.002), both in favor of CRT. Multivariate analysis adjusted for p16 status continued to show improved outcomes (PFS and LRC) for CRT. The 5-year LRC was significantly better with CRT vs. BRT both in the p16+ subgroup (p=0.01) and in p16- or unknown subgroup (p=0.02), and 5-year PFS was of non-significant trend of improvement with CRT vs. BRT in both subgroups (p=0.07 in p16+ and p=0.09 in p16- or unknown, respectively). In the subset of oropharyngeal cancer patients with HPV/p16 status available (n=88), MVA after adjusted for other clinical co-variates showed a non-significant trend of improvement of LRC with CRT compared with BRT (HR=0.4, 95%CI, 0.1-1.0; p=0.06). CONCLUSION: Our long-term results suggested better outcomes in LAHNSCC patients receiving concurrent cisplatin over cetuximab regardless of HPV/p16 status.
    [Abstract] [Full Text] [Related] [New Search]